EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Assessing Trans-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins

John T Powell iD, Ruhul Kayesh, Alexandra Ballesteros-Perez, Khondoker Alam, Pascaline Niyonshuti, Erik J Soderblom, Kai Ding, Chao Xu iD, Wei Yue

Pharmaceutics · 31.12.2023 · 16 (1) · 63

DOI: 10.3390/pharmaceutics16010063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 31.12.2023. Verfasst von John T Powell und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Organic anion transporting polypeptide (OATP) 1B1 and OATP1B3 are key determinants of drug–drug interactions (DDIs). Various drugs including the calcineurin inhibitor (CNI) cyclosporine A (CsA) exert preincubation-induced trans-inhibitory effects upon OATP1B1 and/or OATP1B3 (abbreviated as OATP1B1/3) by unknown mechanism(s). OATP1B1/3 are phosphoproteins; calcineurin, which dephosphorylates and regulates numerous phosphoproteins, has not previously been investigated in the context of preincubation-induced trans-inhibition of OATP1B1/3. Herein, we compare the trans-inhibitory effects exerted on OATP1B1 and OATP1B3 by CsA, the non-analogous CNI tacrolimus, and the non-CNI CsA analogue SCY-635 in transporter-overexpressing human embryonic kidney (HEK) 293 stable cell lines. Preincubation (10–60 min) with tacrolimus (1–10 µM) rapidly and significantly reduces OATP1B1- and OATP1B3-mediated transport up to 0.18 ± 0.03- and 0.20 ± 0.02-fold compared to the control, respectively. Both CsA and SCY-635 can trans-inhibit OATP1B1, with the inhibitory effects progressively increasing over a 60 min preincubation time. At each equivalent preincubation time, CsA has greater trans-inhibitory effects toward OATP1B1 than SCY-635. Preincubation with SCY-635 for 60 min yielded IC50 of 2.2 ± 1.4 µM against OATP1B1, which is ~18 fold greater than that of CsA (0.12 ± 0.04 µM). Furthermore, a proteomics-based screening for protein interactors was used to examine possible proteins and processes contributing to OATP1B1/3 regulation and preincubation-induced inhibition by CNIs and other drugs. A total of 861 and 357 proteins were identified as specifically associated with OATP1B1 and OATP1B3, respectively, including various protein kinases, ubiquitin-related enzymes, the tacrolimus (FK506)-binding proteins FKBP5 and FKBP8, and several known regulatory targets of calcineurin. The current study reports several novel findings that expand our understanding of impaired OATP1B1/3 function; these include preincubation-induced trans-inhibition of OATP1B1/3 by the CNI tacrolimus, greater preincubation-induced inhibition by CsA compared to its non-CNI analogue SCY-635, and association of OATP1B1/3 with various proteins relevant to established and candidate OATP1B1/3 regulatory processes.

Schlagwörter

Stichwörter der Autor:innen

OATP1B1OATP1B3SCY-635calcineurincyclosporine Adrug transportdrug–drug interactionsorganic anion transporting polypeptidetacrolimustrans-inhibition

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, USA.
  • Proteomics and Metabolomics Core Facility, Duke University School of Medicine, Durham, NC 27708, USA.
  • Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

ORCID-Profile: John T Powell, Chao Xu

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • NCI NIH HHS
  • NIH R01
  • American Foundation of Pharmaceutical Education (AB)
  • the Presbyterian Health Foundation

Zitieren

APA

Powell, J. T., Kayesh, R., Ballesteros-Perez, A., Alam, K., Niyonshuti, P., Soderblom, E. J., Ding, K., Xu, C., & Yue, W. (2023). Assessing Trans-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins. Pharmaceutics, 16(1), 63. https://doi.org/10.3390/pharmaceutics16010063

Vancouver

Powell JT, Kayesh R, Ballesteros-Perez A, Alam K, Niyonshuti P, Soderblom EJ, et al. Assessing Trans-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins. Pharmaceutics. 2023;16(1):63. doi:10.3390/pharmaceutics16010063

BibTeX
@article{Powell2023,
  author = {Powell, John T and Kayesh, Ruhul and Ballesteros-Perez, Alexandra and Alam, Khondoker and Niyonshuti, Pascaline and Soderblom, Erik J and Ding, Kai and Xu, Chao and Yue, Wei},
  title = {Assessing Trans-Inhibition of OATP1B1 and OATP1B3 by Calcineurin and/or PPIase Inhibitors and Global Identification of OATP1B1/3-Associated Proteins},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {16},
  number = {1},
  pages = {63},
  doi = {10.3390/pharmaceutics16010063}
}
Kostenlos starten →